Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OVR063
MIFTS: 48

Overnutrition

Categories: Metabolic diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Overnutrition

About this section

MalaCards integrated aliases for Overnutrition:

Name: Overnutrition 12 44 15 73

Classifications:

MalaCards categories:
Global: Metabolic diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:654
MeSH 44 D044343
UMLS 73 C1257763
Sources

Summaries for Overnutrition

About this section
MalaCards based summary : Overnutrition is related to nutritional deficiency disease and gestational diabetes. An important gene associated with Overnutrition is LEP (Leptin), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. The drugs Aspirin and Moxonidine have been mentioned in the context of this disorder. Affiliated tissues include liver, thyroid and heart, and related phenotypes are homeostasis/metabolism and adipose tissue

Wikipedia : 76 Overnutrition or hyperalimentation is a form of malnutrition in which the intake of nutrients is... more...

Sources

Related Diseases for Overnutrition

About this section

Diseases related to Overnutrition via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Related Disease Score Top Affiliating Genes
1 nutritional deficiency disease 32.1 CRP GHRL IL6 LEP
2 gestational diabetes 30.6 ADIPOQ INS LEP RETN
3 fatty liver disease, nonalcoholic 1 30.4 ADIPOQ INS LEP RETN
4 fatty liver disease 30.3 ADIPOQ IL6 INS LEP LEPR
5 liver disease 30.3 ADIPOQ IL6 INS LEP LEPR
6 glucose intolerance 30.1 ADIPOQ CRP GHRL INS LEP LEPR
7 lipodystrophy, familial partial, type 1 10.3 INS LEP PPARG
8 complete generalized lipodystrophy 10.3 INS LEP PPARG
9 lipodystrophy, congenital generalized, type 1 10.3 ADIPOQ INS LEP
10 nonalcoholic steatohepatitis 10.3 ADIPOQ INS LEP
11 idiopathic recurrent pericarditis 10.3 ADIPOQ LEP RETN
12 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.3 CRP INS LEP
13 endocrine pancreas disease 10.3 ADIPOQ INS LEP
14 malignant otitis externa 10.3 CRP INS
15 idiopathic edema 10.3 ADIPOQ INS PPARG
16 functional gastric disease 10.3 GHRL INS TRPV1
17 familial partial lipodystrophy 10.3 INS LEP PPARG
18 acute insulin response 10.3 CRP INS UCP1
19 abdominal obesity-metabolic syndrome 1 10.3 ADIPOQ INS LEP PPARG
20 hypercholesterolemia, autosomal recessive 10.3 AGRP LEP NPY
21 coronary artery aneurysm 10.3 ADIPOQ LEP RETN
22 acanthosis nigricans 10.3 ADIPOQ INS LEP PPARG
23 diabetic neuropathy 10.3 INS LEP TRPV1
24 anovulation 10.3 CRP INS LEP
25 achromatopsia 3 10.3 AGRP MC4R TRPV1
26 inherited metabolic disorder 10.3 ADIPOQ CRP INS LEP
27 severe pre-eclampsia 10.3 ADIPOQ LEP LEPR
28 hyperglycemia 10.3 ADIPOQ INS LEP PPARG
29 obesity-hypoventilation syndrome 10.3 ADIPOQ IL6 LEP RETN
30 cold agglutinin disease 10.3 CRP IL6
31 sleep disorder 10.3 CRP IL6 INS LEP
32 uremia 10.3 CRP INS LEP RETN
33 extrinsic cardiomyopathy 10.3 CRP IL6 TNNI3K
34 intermittent explosive disorder 10.3 CRP IL6 NPY
35 aging 10.3
36 bacterial pneumonia 10.3 CRP IL6 TRPV1
37 acquired generalized lipodystrophy 10.3 ADIPOQ INS LEP PPARG RETN
38 urinary system disease 10.3 CRP IL6 INS TRPV1
39 hyperthyroidism 10.3 GHRL INS LEP
40 cystitis 10.3 CRP IL6 TRPV1
41 cerebrovascular disease 10.3 ADIPOQ CRP IL6 INS
42 nervous system disease 10.3 CRP IL6 INS TRPV1
43 intestinal disease 10.3 CRP GHRL IL6 TRPV1
44 postgastrectomy syndrome 10.3 INS PYY
45 apnea, obstructive sleep 10.3 ADIPOQ CRP IL6 INS LEP
46 bone inflammation disease 10.3 CRP IL6 TRPV1
47 end stage renal failure 10.3 CRP IL6 LEP
48 pancreas disease 10.3 CRP IL6 INS LEP TRPV1
49 hypercholesterolemia, familial 10.2 AGRP CRP INS NPY
50 gastroesophageal reflux 10.2 GHRL PYY TRPV1

Graphical network of the top 20 diseases related to Overnutrition:



Diseases related to Overnutrition
Sources

Symptoms & Phenotypes for Overnutrition

About this section

MGI Mouse Phenotypes related to Overnutrition:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.48 ADIPOQ AGRP CRAT CRP FGF1 FTO
2 adipose tissue MP:0005375 10.46 ADIPOQ AGRP FTO GHRL IL6 INS
3 behavior/neurological MP:0005386 10.39 ADIPOQ AGRP FTO GHRL IL6 INS
4 growth/size/body region MP:0005378 10.37 ADIPOQ AGRP CRAT FTO IL6 INS
5 cardiovascular system MP:0005385 10.31 ADIPOQ CRAT CRP IL6 INS LEP
6 cellular MP:0005384 10.26 ADIPOQ CRAT IL6 INS LEP LEPR
7 immune system MP:0005387 10.23 ADIPOQ CRP FTO IL6 INS LEP
8 liver/biliary system MP:0005370 10.22 ADIPOQ AGRP FTO IL6 INS LEP
9 integument MP:0010771 10.09 ADIPOQ FTO IL6 INS LEP LEPR
10 digestive/alimentary MP:0005381 10.05 GHRL IL6 INS LEP LEPR NPY
11 nervous system MP:0003631 10.03 ADIPOQ AGRP FGF1 IL6 INS LEP
12 muscle MP:0005369 9.97 ADIPOQ CRAT IL6 INS LEP LEPR
13 neoplasm MP:0002006 9.87 ADIPOQ IL6 LEP LEPR MC4R PPARG
14 normal MP:0002873 9.85 AGRP FGF1 GHRL INS LEPR MC4R
15 renal/urinary system MP:0005367 9.61 ADIPOQ FTO IL6 INS LEP LEPR
16 skeleton MP:0005390 9.36 ADIPOQ FTO IL6 INS LEP LEPR
Sources

Drugs & Therapeutics for Overnutrition

About this section

Drugs for Overnutrition (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 633)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Early Phase 1 50-78-2 2244
2
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
3
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
4
Enoxaparin Approved Phase 4,Phase 1,Phase 2 9005-49-6 772
5
Dalteparin Approved Phase 4,Phase 1 9005-49-6
6
chenodeoxycholic acid Approved Phase 4 474-25-9 10133
7 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
8
Rocuronium Approved Phase 4,Phase 2,Not Applicable 119302-91-9, 143558-00-3 441290
9
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
10
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 57-27-2 5288826
11
Acetaminophen Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 103-90-2 1983
12
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
13
Hydroxocobalamin Approved Phase 4,Phase 2 13422-51-0 11953898 44475014
14
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 2 13422-55-4
15
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
16
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
17
Irbesartan Approved, Investigational Phase 4,Not Applicable 138402-11-6 3749
18
Angiotensin II Approved, Investigational Phase 4,Early Phase 1,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
19
Saxagliptin Approved Phase 4 361442-04-8 11243969
20
Heparin Approved, Investigational Phase 4,Not Applicable 9005-49-6 772 46507594
21
Nadroparin Approved, Investigational Phase 4
22
Anastrozole Approved, Investigational Phase 4,Not Applicable 120511-73-1 2187
23
Midazolam Approved, Illicit Phase 4,Phase 1,Not Applicable 59467-70-8 4192
24
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 141758-74-9 15991534
25
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1 204656-20-2 44147092
26
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
27
leucovorin Approved Phase 4,Not Applicable 58-05-9 6006 143
28
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 7440-66-6
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 437-38-7 3345
30
Methylene blue Approved, Investigational Phase 4,Phase 1,Phase 2 61-73-4
31
Empagliflozin Approved Phase 4 864070-44-0
32
Glycerol Approved, Investigational Phase 4,Not Applicable 56-81-5 753
33
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
34
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
35
Phentermine Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 122-09-8 4771
36
Topiramate Approved Phase 4,Phase 3,Phase 2,Not Applicable 97240-79-4 5284627
37
Cefazolin Approved Phase 4,Not Applicable 25953-19-9 656510 33255
38
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
39
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
40
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 83150-76-9 383414 6400441
41
Tocopherol Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 1406-66-2 14986
42
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
43
Ibuprofen Approved Phase 4,Not Applicable 15687-27-1 3672
44
Ursodeoxycholic acid Approved, Investigational Phase 4,Not Applicable 128-13-2 31401
45
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
46
Orlistat Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 96829-58-2 3034010
47
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
48
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
49
Sulfamethoxazole Approved Phase 4 723-46-6 5329
50
Dapsone Approved, Investigational Phase 4 80-08-0 2955

Interventional clinical trials:

(show top 50) (show all 2435)
# Name Status NCT ID Phase Drugs
1 Type 2 Diabetes Mellitus and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
2 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
3 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
4 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
5 The Therapeutic Effect of Catgut Embedding in Obesity Unknown status NCT02276235 Phase 4
6 Prevention and Control of Obesity in Primary School Children in Tehran Unknown status NCT02082080 Phase 4
7 Anti Xa Levels Under Two Different Regimens of Enoxaparin VTE Prophylaxis After Sleeve Gastrectomy for Morbid Obesity Unknown status NCT01970202 Phase 4 40mg Enoxaparin;60mg Enoxaparin
8 Pharmacokinetics of Dexmedetomidine in Morbid Obesity Unknown status NCT01864187 Phase 4 Dexmedetomidine
9 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
10 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity Unknown status NCT01550601 Phase 4
11 The Effect of Vitamin A Supplementation on Cytokine Profile in Obesity Unknown status NCT01405352 Phase 4
12 Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Unknown status NCT02952963 Phase 4 Chenodeoxycholic Acid;Colesevelam
13 Laparoscopic Bariatric Surgery: Impact of Deep Neuromuscular Block on Surgical Conditions Unknown status NCT02118844 Phase 4 rocuronium
14 VAS Correlation With BMI Unknown status NCT02017314 Phase 4 Morphine
15 Pharmacokinetics of Acetaminophen in Morbidly Obese Patients Unknown status NCT01764555 Phase 4 acetaminophen 2 g
16 Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
17 Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
18 Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
19 Vitamin Deficiencies and Suppletion in Morbid Obesity Unknown status NCT02270749 Phase 4 Hydroxocobalamin;FitForMe vitamin B12
20 Effect of Laparoscopic Sleeve Gastrectomy in the Morbidly Obese, Kidney Transplant Candidate Unknown status NCT01913392 Phase 4
21 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
22 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
23 The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension Unknown status NCT01360710 Phase 4 Moxonidine;Irbesartan
24 Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
25 Prophylaxis of Venous Thromboembolism After Bariatric Surgery Unknown status NCT02295150 Phase 4 Nadroparin
26 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Unknown status NCT02959853 Phase 4 Anastrazole
27 CYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model Drug Unknown status NCT01519726 Phase 4 Midazolam
28 Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging Completed NCT02833415 Phase 4 [U-13C3] glycerol;Empagliflozin;Placebo (for Empagliflozin)
29 Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers Completed NCT01090141 Phase 4 Micafungin;Micafungin
30 Bread in Overweight/Obesity Treatment Completed NCT01223989 Phase 4
31 BIFI-OBESE: Clinical Trial in Paediatric Obesity Completed NCT03261466 Phase 4 Bifidobacterium breve BR03 and Bifidobacterium breve B632;Placebos
32 A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents Completed NCT02714062 Phase 4 Placebo;VI-0521 Mid Dose;VI-0521 Top Dose
33 Use of Metformin in Treatment of Childhood Obesity Completed NCT02274948 Phase 4 Metformin;Placebo
34 Auricular Acupuncture in the Treatment of Obesity Completed NCT02269371 Phase 4
35 GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men Completed NCT02170324 Phase 4 Exenatide;Placebo
36 Increased Cefazolin During Cesarean Delivery in Obese Population Completed NCT02049944 Phase 4 Cefazolin
37 A Toolbox Approach to Obesity Treatment in Primary Care Completed NCT01922934 Phase 4 Obesity pharmacotherapy
38 Enoxaparin Dosing in Obesity Completed NCT01798550 Phase 4 Enoxaparin
39 Evaluation of a Commercial Gaming Impact in a Childhood Obesity Intervention Completed NCT01757925 Phase 4
40 Clinical Trial Between Laparoscopic Gastric Bypass and Laparoscopic Vertical Banded Gastroplasty for Morbid Obesity Completed NCT01639677 Phase 4
41 Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations Completed NCT01307930 Phase 4 Anidulafungin
42 A Randomized Clinical Trial of Home-based Exercise Combined With a Slight Caloric Restriction on Obesity Prevention Among Women Completed NCT01206413 Phase 4
43 Effect of Weight and/or Obesity on Caspofungin Drug Concentrations Completed NCT01062165 Phase 4 Caspofungin
44 Effects of Re-Feeding Duration on Weight Maintenance After Weight Loss With Very-Low-Energy Diets (VLEDs) Completed NCT00694811 Phase 4
45 Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band Completed NCT00543140 Phase 4
46 A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients Completed NCT00171613 Phase 4 Octreotide
47 Pediatric Hypothalamic Obesity Completed NCT00076362 Phase 4 Sandostatin LAR
48 Effects of Vitamin E Supplementation on Free Radicals and Fat Level of Obese Adolescence in Jakarta, Indonesia Completed NCT03358524 Phase 4 Vitamin E 400 UNT;Placebo oral capsule
49 Dosing Obese With Noxafil® Under a Trial (DONUT) Completed NCT03246386 Phase 4 Posaconazole Injection [Noxafil] 300mg;Posaconazole Injection [Noxafil] 400mg
50 Micafungin Pharmacokinetics in Obese Patients Completed NCT03102658 Phase 4 Micafungin

Search NIH Clinical Center for Overnutrition

Cochrane evidence based reviews: overnutrition

Sources

Genetic Tests for Overnutrition

About this section
Sources

Anatomical Context for Overnutrition

About this section

MalaCards organs/tissues related to Overnutrition:

41
Liver, Thyroid, Heart, Brain, Bone, Kidney, Pancreas
Sources

Publications for Overnutrition

About this section

Articles related to Overnutrition:

(show top 50) (show all 245)
# Title Authors Year
1
Maternal overnutrition programs epigenetic changes in the regulatory regions of hypothalamic Pomc in the offspring of rats. ( 29777232 )
2018
2
Fetal Overnutrition and Adolescent Hepatic Fat Fraction: the Exploring Perinatal Outcomes in Children Study. ( 29046229 )
2018
3
Sociodemographic and geographical inequalities in under- and overnutrition among children and mothers in Bangladesh: a spatial modelling approach to a nationally representative survey. ( 29717690 )
2018
4
Maternal overnutrition leads to cognitive and neurochemical abnormalities in C57BL/6 mice. ( 29390923 )
2018
5
Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease. ( 29956204 )
2018
6
Prevalence and sociodemographic determinants of adult obesity: a large representative household survey in a resource-constrained African setting with double burden of undernutrition and overnutrition. ( 29599385 )
2018
7
Remodeling of the Acetylproteome by SIRT3 Manipulation Fails to Affect Insulin Secretion or I^ Cell Metabolism in the Absence of Overnutrition. ( 29972782 )
2018
8
Metformin influences on respiratory system in obese mice induced by postnatal overnutrition. ( 28963087 )
2018
9
The Hypothalamic Inflammatory/Gliosis Response to Neonatal Overnutrition Is Sex and Age Dependent. ( 29077836 )
2018
10
Epigenetic programming at the Mogat1 locus may link neonatal overnutrition with long-term hepatic steatosis and insulin resistance. ( 29812971 )
2018
11
Novel Insights into How Overnutrition Disrupts the Hypothalamic Actions of Leptin. ( 29632515 )
2018
12
Neonatal Overnutrition Increases Testicular Size and Expression of Luteinizing Hormone I^-Subunit in Peripubertal Male Rats. ( 29706935 )
2018
13
Maternal overnutrition by hypercaloric diets programs hypothalamic mitochondrial fusion and metabolic dysfunction in rat male offspring. ( 29991958 )
2018
14
Maternal Overnutrition Programs Central Inflammation and Addiction-Like Behavior in Offspring. ( 30027100 )
2018
15
Both Maternal Low-Protein and Neonatal Overnutrition Result in Similar Changes to Glomerular Morphology and Renal Cortical Oxidative Stress Measures in Male Wistar Rats. ( 30058348 )
2018
16
The transcriptome of the rat subfornical organ is altered in response to early postnatal overnutrition. ( 30135952 )
2018
17
Reuniting overnutrition and undernutrition, macronutrients, and micronutrients. ( 30171821 )
2018
18
Postnatal overnutrition alters the orexigenic effects of melanin-concentrating hormone (MCH) and reduces MCHR1 hypothalamic expression on spontaneous feeding and fasting. ( 30196088 )
2018
19
Overnutrition: Does Complementary Feeding Play a Role? ( 30196296 )
2018
20
Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition. ( 30226474 )
2018
21
UBE3A suppresses overnutrition-induced expression of the steatosis target genes of MLL4 by degrading MLL4. ( 30230575 )
2018
22
Effect of maternal antioxidant supplementation and/or exercise practice during pregnancy on postnatal overnutrition induced by litter size reduction: Brain redox homeostasis at weaning. ( 30232036 )
2018
23
Overnutrition and Scholastic Achievement: Is There a Relationship? An 8-Year Follow-Up Study. ( 30308520 )
2018
24
Transgenerational transmission of hedonic behaviors and metabolic phenotypes induced by maternal overnutrition. ( 30315171 )
2018
25
Intergenerational impact of maternal overnutrition and obesity throughout pregnancy in sheep on metabolic syndrome in grandsons and granddaughters. ( 28527530 )
2017
26
Placental Lipid and Fatty Acid Transfer in Maternal Overnutrition. ( 28301855 )
2017
27
Exacerbation of liver steatosis following exposure to famine and overnutrition. ( 28499082 )
2017
28
From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions. ( 28677122 )
2017
29
Maternal Nutrition during Pregnancy Affects Testicular and Bone Development, Glucose Metabolism and Response to Overnutrition in Weaned Horses Up to Two Years. ( 28081146 )
2017
30
Fetal overnutrition and offspring insulin resistance and I^-cell function: the Exploring Perinatal Outcomes among Children (EPOCH) study. ( 28636758 )
2017
31
Double burden of diseases worldwide: coexistence of undernutrition and overnutrition-related non-communicable chronic diseases. ( 28940822 )
2017
32
Maternal low intensity physical exercise prevents obesity in offspring rats exposed to early overnutrition. ( 28794439 )
2017
33
Effects of early overnutrition on the renal response to Ang II and expression of RAAS components in rat renal tissue. ( 28958692 )
2017
34
Undernutrition and Overnutrition Burden for Diseases in Developing Countries: The Role of Oxidative Stress Biomarkers to Assess Disease Risk and Interventional Strategies. ( 28594364 )
2017
35
An efficient electrochemiluminescence amplification strategy via bis-co-reaction accelerator for sensitive detection of laminin to monitor overnutrition associated liver damage. ( 28697444 )
2017
36
Postnatal overnutrition affects metabolic and vascular function reflected by physiological and histological changes in the aorta of adult Wistar rats. ( 29115861 )
2017
37
Differential effects of late gestation maternal overnutrition on the regulation of surfactant maturation in fetal and postnatal life. ( 28759122 )
2017
38
Preparing for the first breath: in the developing lung, maternal overnutrition takes centre stage. ( 28925540 )
2017
39
Developmental programming of the pancreatic islet by in utero overnutrition. ( 29657386 )
2017
40
Overnutrition, ectopic lipid and the metabolic syndrome. ( 27194746 )
2016
41
Early life overnutrition induced by litter size manipulation decreases social play behavior in adolescent male rats. ( 27469432 )
2016
42
Overnutrition during lactation leads to impairment in insulin signaling, up-regulation of GLUT1 and increased mitochondrial carbohydrate oxidation in heart of weaned mice. ( 26608021 )
2016
43
Food Insecurity Is Associated with Undernutrition but Not Overnutrition in Ecuadorian Women from Low-Income Urban Neighborhoods. ( 27110253 )
2016
44
Age and sex dependent effects of early overnutrition on metabolic parameters and the role of neonatal androgens. ( 27195103 )
2016
45
Enhanced sensitivity to drugs of abuse and palatable foods following maternal overnutrition. ( 27701408 )
2016
46
From Undernutrition to Overnutrition: The Evolution of Overweight and Obesity among Young Men in Switzerland since the 19th Century. ( 27544200 )
2016
47
FGF1 Mediates Overnutrition-Induced Compensatory I^-Cell Differentiation. ( 26420862 )
2015
48
Postnatal overnutrition programs the thyroid hormone metabolism and function in adulthood. ( 26203167 )
2015
49
Postnatal prebiotic fibre intake mitigates some detrimental metabolic outcomes of early overnutrition in rats. ( 26407845 )
2015
50
Neonatal overnutrition causes early alterations in the central response to peripheral ghrelin. ( 25685686 )
2015
Sources

Variations for Overnutrition

About this section
Sources

Expression for Overnutrition

About this section
Search GEO for disease gene expression data for Overnutrition.
Sources

Pathways for Overnutrition

About this section

Pathways related to Overnutrition according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 66
Show member pathways
 13.41 ADIPOQ IL6 INS LEP LEPR PPARG
2
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 65
Show member pathways
 12.59 ADIPOQ IL6 INS LEP RETN SOCS3
3
Glucose / Energy Metabolism 4
12.37 ADIPOQ FTO INS PPARG UCP1
4
Prolactin Signaling Pathway 1 37
Show member pathways
 12.33 INS LEP LEPR SOCS3
5
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.27 ADIPOQ INS LEP LEPR PPARG
6
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 12.25 IL6 LEP LEPR SOCS3
8
Insulin resistance 37
Show member pathways
 11.8 IL6 INS SOCS3
9
Type II diabetes mellitus 37 1
Show member pathways
 11.73 ADIPOQ INS SOCS3
10
IL6-mediated signaling events 1
Show member pathways
 11.67 CRP IL6 SOCS3
11
PPAR signaling pathway 37
11.58 ADIPOQ PPARG UCP1
12
ATF-2 transcription factor network 1
11.43 IL6 INS SOCS3
13
Signaling events mediated by PTP1B 1
11.37 INS LEP LEPR SOCS3
14
Differentiation Pathway 1
11.35 FGF1 IL6 INS
15
Adipogenesis 1
11.35 ADIPOQ IL6 INS LEP PPARG RETN
16
Adipocytokine signaling pathway 37
11.27 ADIPOQ AGRP LEP LEPR NPY SOCS3
17
Development_Leptin signaling via JAK/STAT and MAPK cascades 22
Show member pathways
 11.03 CRP LEP LEPR SOCS3
18
Differentiation of white and brown adipocyte 1
10.98 ADIPOQ LEP PPARG
19
Syndecan-3-mediated signaling events 1
10.83 AGRP MC4R
20
Transcription factor regulation in adipogenesis 1
10.8 ADIPOQ IL6 LEP PPARG
21
FTO Obesity Variant Mechanism 1
10.43 FTO UCP1
Sources

GO Terms for Overnutrition

About this section

Cellular components related to Overnutrition according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 ADIPOQ AGRP CRP FGF1 GHRL IL6
2 extracellular space GO:0005615 9.36 ADIPOQ AGRP CRP FGF1 GHRL IL6

Biological processes related to Overnutrition according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 response to insulin GO:0032868 9.85 AGRP LEP MC4R RETN
2 negative regulation of inflammatory response GO:0050728 9.84 ADIPOQ GHRL SOCS3
3 neuropeptide signaling pathway GO:0007218 9.84 AGRP NPY PYY
4 circadian rhythm GO:0007623 9.83 ADIPOQ AGRP LEP
5 response to nutrient GO:0007584 9.82 ADIPOQ LEP PPARG
6 glucose metabolic process GO:0006006 9.81 ADIPOQ GHRL INS LEP
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 IL6 LEP SOCS3
8 regulation of blood pressure GO:0008217 9.8 LEP NPY PPARG
9 response to nutrient levels GO:0031667 9.78 ADIPOQ GHRL LEP UCP1
10 hormone-mediated signaling pathway GO:0009755 9.77 AGRP GHRL PPARG
11 glucose homeostasis GO:0042593 9.77 ADIPOQ INS LEP LEPR PPARG
12 acute-phase response GO:0006953 9.74 CRP IL6 INS
13 energy reserve metabolic process GO:0006112 9.71 LEP LEPR MC4R
14 negative regulation of gluconeogenesis GO:0045721 9.7 ADIPOQ INS LEPR
15 negative regulation of collagen biosynthetic process GO:0032966 9.68 IL6 PPARG
16 positive regulation of cellular protein metabolic process GO:0032270 9.68 ADIPOQ INS
17 positive regulation of insulin receptor signaling pathway GO:0046628 9.68 INS LEP
18 regulation of fat cell differentiation GO:0045598 9.67 LEP PPARG
19 fatty acid oxidation GO:0019395 9.67 ADIPOQ PPARG
20 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.67 ADIPOQ CRP PPARG
21 interleukin-6-mediated signaling pathway GO:0070102 9.66 IL6 SOCS3
22 central nervous system neuron development GO:0021954 9.65 LEP NPY
23 sexual reproduction GO:0019953 9.64 LEP LEPR
24 negative regulation of blood vessel diameter GO:0097756 9.64 CRP INS
25 leptin-mediated signaling pathway GO:0033210 9.63 LEP LEPR
26 regulation of feeding behavior GO:0060259 9.63 AGRP LEPR MC4R
27 negative regulation of acute inflammatory response GO:0002674 9.62 INS PPARG
28 positive regulation of feeding behavior GO:2000253 9.61 AGRP GHRL
29 regulation of bone remodeling GO:0046850 9.61 LEP LEPR
30 negative regulation of lipid storage GO:0010888 9.61 CRP IL6 LEP
31 regulation of brown fat cell differentiation GO:0090335 9.59 FTO LEP
32 regulation of metabolic process GO:0019222 9.58 LEP MC4R
33 positive regulation of appetite GO:0032100 9.58 GHRL NPY
34 diet induced thermogenesis GO:0002024 9.58 MC4R TRPV1 UCP1
35 bone growth GO:0098868 9.56 LEP LEPR
36 feeding behavior GO:0007631 9.56 AGRP MC4R NPY PYY
37 positive regulation of cold-induced thermogenesis GO:0120162 9.55 ADIPOQ GHRL LEP LEPR UCP1
38 negative regulation of feeding behavior GO:2000252 9.5 INS MC4R RETN
39 regulation of signaling receptor activity GO:0010469 9.32 ADIPOQ AGRP FGF1 GHRL IL6 INS
40 adult feeding behavior GO:0008343 9.26 AGRP GHRL LEP NPY

Molecular functions related to Overnutrition according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.55 ADIPOQ AGRP CRAT LEP NPY
2 G protein-coupled receptor binding GO:0001664 9.43 GHRL NPY PYY
3 hormone activity GO:0005179 9.17 ADIPOQ GHRL INS LEP NPY PYY
4 neuropeptide hormone activity GO:0005184 9.13 AGRP NPY PYY
Sources

Sources for Overnutrition

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....